XNAS
ORMP
Market cap171mUSD
Oct 08, Last price
4.20USD
1D
-3.89%
1Q
3.96%
Jan 2017
-31.37%
IPO
-65.00%
Name
Oramed Pharmaceuticals Inc
Chart & performance
P/E
2.68
P/S
85.94
EPS
1.57
Div yield, %
—
Shrs. gr., 5y
15.62%
Rev. gr., 5y
-5.90%
Revenues
2m
Net income
64m
P
CFO
-9m
L+8.71%
Dividend
Jan 16, 20260.25 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Key people
Nadav Kidron
Chairman of the Board, President, Chief Executive Officer · since 2022
Joshua Hexter
Chief Operating and Business Officer · since 2019
Miriam Kidron
Chief Scientific Officer, Director · since 2006
Avraham Gabay
Chief Financial Officer, Treasurer, Secretary · since 2024
Daniel Aghion
Independent Director · since 2024
Arie Mayer
Independent Director · since 2019
Yehuda Reznick
Independent Director · since 2024
Benjamin Shapiro
Independent Director · since 2023
Legal address
c/o Vcorp Services, LLC, 1013 Center Road, Suite 403-B
Wilmington, DE 19805
US
Wilmington, DE 19805
US
Headquarters
142 W. 57th Street, 11th floor
New York, NY 10019
US
New York, NY 10019
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑08 | 2020‑08 | 2019‑08 | 2018‑08 | 2017‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||